BioScrip (NASDAQ: BIOS) is one of 15 public companies in the “Hospitals, Clinics & Primary Care Services” industry, but how does it compare to its rivals? We will compare BioScrip to related companies based on the strength of its institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings.

Analyst Recommendations

This is a breakdown of current ratings and target prices for BioScrip and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioScrip 0 0 4 0 3.00
BioScrip Competitors 59 327 512 9 2.52

BioScrip currently has a consensus target price of $3.75, suggesting a potential upside of 40.45%. As a group, “Hospitals, Clinics & Primary Care Services” companies have a potential upside of 19.54%. Given BioScrip’s stronger consensus rating and higher probable upside, research analysts clearly believe BioScrip is more favorable than its rivals.

Profitability

This table compares BioScrip and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioScrip -8.42% N/A -8.01%
BioScrip Competitors 3.55% 3.42% 4.26%

Institutional & Insider Ownership

84.7% of BioScrip shares are owned by institutional investors. Comparatively, 69.6% of shares of all “Hospitals, Clinics & Primary Care Services” companies are owned by institutional investors. 0.8% of BioScrip shares are owned by insiders. Comparatively, 10.4% of shares of all “Hospitals, Clinics & Primary Care Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares BioScrip and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioScrip $935.59 million -$41.50 million -3.93
BioScrip Competitors $1.06 billion -$22.56 million 763.00

BioScrip’s rivals have higher revenue and earnings than BioScrip. BioScrip is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

BioScrip has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, BioScrip’s rivals have a beta of 1.47, meaning that their average share price is 47% more volatile than the S&P 500.

Summary

BioScrip rivals beat BioScrip on 8 of the 12 factors compared.

About BioScrip

BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.